BIOMAT Database Logo BIOMAT Database Logo

Clinical evaluation of 5-hydroxy-L-tryptophan as an antidepressant drug. 1978

T Nakajima, and Y Kudo, and Z Kaneko

Effectiveness of 5-hydroxy-L-trytophan as an antidepressant drug was studied with 59 patients with depressive symptoms using Rating Scale for Depression made by Clinico-Psychopharmacology Research Group in Japan for a preparatory step of a double blind clinical study of 5-hydroxy-L-tryptophan treatment of depression. A daily dose of 150--300 mg of 5-hydroxyl-L-tryptophan was administered for three weeks. Favorable responses were observed in 40 patients (67.8%), of whom 13 patients were markedly improved. These effects were noticed in 32 patients (80% of the improved patients) within a week of the treatment. Analysis of General Improvement Rating in the various subtypes of depressive symptoms indicated that endogenous depression and involutional or senile depression were the preferable indication of 5-hydroxy-L-tryptophan loading. The main side effects of 5-hydroxy-L-tryptophan were gastrointestinal disturbances which were minimized by the simultaneous administration of metoclopromide or trihexyphenidyl.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006916 5-Hydroxytryptophan The immediate precursor in the biosynthesis of SEROTONIN from tryptophan. It is used as an antiepileptic and antidepressant. 5-HTP,Hydroxytryptophan,Oxitriptan,Oxytryptophan,Tryptophan, 5-Hydroxy-,5 Hydroxytryptophan,5-Hydroxy- Tryptophan,Tryptophan, 5 Hydroxy
D000275 Adjustment Disorders Maladaptive reactions to identifiable psychosocial stressors occurring within a short time after onset of the stressor. They are manifested by either impairment in social or occupational functioning or by symptoms (depression, anxiety, etc.) that are in excess of a normal and expected reaction to the stressor. Anniversary Reaction,Depression, Reactive,Reactive Disorders,Transient Situational Disturbance,Adjustment Disorder,Anniversary Reactions,Depressions, Reactive,Disorder, Adjustment,Disorder, Reactive,Disorders, Adjustment,Disorders, Reactive,Disturbance, Transient Situational,Disturbances, Transient Situational,Reaction, Anniversary,Reactions, Anniversary,Reactive Depression,Reactive Depressions,Reactive Disorder,Situational Disturbance, Transient,Situational Disturbances, Transient,Transient Situational Disturbances
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000928 Antidepressive Agents Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. Antidepressant,Antidepressant Drug,Antidepressant Medication,Antidepressants,Antidepressive Agent,Thymoanaleptic,Thymoanaleptics,Thymoleptic,Thymoleptics,Antidepressant Drugs,Agent, Antidepressive,Drug, Antidepressant,Medication, Antidepressant

Related Publications

T Nakajima, and Y Kudo, and Z Kaneko
L-tryptophan as an antidepressant.
May 1971, Lancet (London, England),
T Nakajima, and Y Kudo, and Z Kaneko
Enzymatic preparation of L-tryptophan and 5-hydroxy-L-tryptophan.
September 1972, FEBS letters,
T Nakajima, and Y Kudo, and Z Kaneko
Safety of 5-hydroxy-L-tryptophan.
April 2004, Toxicology letters,
T Nakajima, and Y Kudo, and Z Kaneko
Occurrence of 5-hydroxy-L-tryptophan as a free plant amino-acid.
April 1966, Nature,
T Nakajima, and Y Kudo, and Z Kaneko
[Treatment of endogenous depression with L-hydroxy-tryptophan (L-5-HTP)].
January 1973, Nihon rinsho. Japanese journal of clinical medicine,
T Nakajima, and Y Kudo, and Z Kaneko
Problems with over-the-counter 5-hydroxy-L-tryptophan.
September 1998, Nature medicine,
T Nakajima, and Y Kudo, and Z Kaneko
Locomotion in the rat after 5-hydroxy-L-tryptophan.
February 1984, European journal of pharmacology,
T Nakajima, and Y Kudo, and Z Kaneko
Enhanced synthesis of 5-hydroxy-l-tryptophan through tetrahydropterin regeneration.
December 2013, AMB Express,
T Nakajima, and Y Kudo, and Z Kaneko
Neuropharmacology of progressive myoclonus epilepsy: response to 5-hydroxy-L-tryptophan.
August 1995, Epilepsia,
T Nakajima, and Y Kudo, and Z Kaneko
Administration of 5-hydroxy-L-tryptophan to individuals with Huntington's chorea.
November 1972, Neurology,
Copied contents to your clipboard!